Literature DB >> 25239120

Elevated micronucleus frequency in patients with type 2 diabetes, dyslipidemia and periodontitis.

Sâmia C T Corbi1, Alliny S Bastos1, Silvana R P Orrico1, Rodrigo Secolin2, Raquel A Dos Santos3, Catarina S Takahashi4, Raquel M Scarel-Caminaga5.   

Abstract

The over-production of reactive oxygen species (ROS) can cause oxidative damage to a large number of molecules, including DNA, and has been associated with the pathogenesis of several disorders, such as diabetes mellitus (DM), dyslipidemia and periodontitis (PD). We hypothesise that the presence of these diseases could proportionally increase the DNA damage. The aim of this study was to assess the micronucleus frequency (MNF), as a biomarker for DNA damage, in individuals with type 2 DM, dyslipidemia and PD. One hundred and fifty patients were divided into five groups based upon diabetic, dyslipidemic and periodontal status (Group 1 - poor controlled DM with dyslipidemia and PD; Group 2 - well-controlled DM with dyslipidemia and PD; Group 3 - without DM with dyslipidemia and PD; Group 4 - without DM, without dyslipidemia and with PD; and Group 5 - without DM, dyslipidemia and PD). Blood analyses were carried out for fasting plasma glucose, HbA1c and lipid profile. Periodontal examinations were performed, and venous blood was collected and processed for micronucleus (MN) assay. The frequency of micronuclei was evaluated by cell culture cytokinesis-block MN assay. The general characteristics of each group were described by the mean and standard deviation and the data were submitted to the Mann-Whitney, Kruskal-Wallis, Multiple Logistic Regression and Spearman tests. The Groups 1, 2 and 3 were similarly dyslipidemic presenting increased levels of total cholesterol, low density lipoprotein cholesterol and triglycerides. Periodontal tissue destruction and local inflammation were significantly more severe in diabetics, particularly in Group 1. Frequency of bi-nucleated cells with MN and MNF, as well as nucleoplasmic bridges, were significantly higher for poor controlled diabetics with dyslipidemia and PD in comparison with those systemically healthy, even after adjusting for age, and considering Bonferroni's correction. Elevated frequency of micronuclei was found in patients affected by type 2 diabetes, dyslipidemia and PD. This result suggests that these three pathologies occurring simultaneously promote an additional role to produce DNA impairment. In addition, the micronuclei assay was useful as a biomarker for DNA damage in individuals with chronic degenerative diseases.
© The Author 2014. Published by Oxford University Press on behalf of the UK Environmental Mutagen Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Mesh:

Year:  2014        PMID: 25239120     DOI: 10.1093/mutage/geu043

Source DB:  PubMed          Journal:  Mutagenesis        ISSN: 0267-8357            Impact factor:   3.000


  8 in total

1.  Cellular and Biochemical Changes in Different Categories of Periodontitis: A Patient-based Study.

Authors:  Fiona Shee; Swati Pralhad; Srikant Natarajan; Nidhi Manaktala; S Arun; Aradhana Marathe
Journal:  J Int Soc Prev Community Dent       Date:  2020-05-07

2.  Expression Profile of Genes Potentially Associated with Adequate Glycemic Control in Patients with Type 2 Diabetes Mellitus.

Authors:  Sâmia Cruz Tfaile Corbi; Alliny Souza Bastos; Rafael Nepomuceno; Thamiris Cirelli; Raquel Alves Dos Santos; Catarina Satie Takahashi; Cristiane S Rocha; Silvana Regina Perez Orrico; Claudia V Maurer-Morelli; Raquel Mantuaneli Scarel-Caminaga
Journal:  J Diabetes Res       Date:  2017-07-25       Impact factor: 4.011

3.  Dyslipidemia rather than Type 2 Diabetes Mellitus or Chronic Periodontitis Affects the Systemic Expression of Pro- and Anti-Inflammatory Genes.

Authors:  Rafael Nepomuceno; Bárbara Scoralick Villela; Sâmia Cruz Tfaile Corbi; Alliny De Souza Bastos; Raquel Alves Dos Santos; Catarina Satie Takahashi; Silvana Regina Perez Orrico; Raquel Mantuaneli Scarel-Caminaga
Journal:  Mediators Inflamm       Date:  2017-02-20       Impact factor: 4.711

4.  Circulating lymphocytes and monocytes transcriptomic analysis of patients with type 2 diabetes mellitus, dyslipidemia and periodontitis.

Authors:  Sâmia C T Corbi; Jaira F de Vasconcellos; Alliny S Bastos; Diego Girotto Bussaneli; Bárbara Roque da Silva; Raquel Alves Santos; Catarina S Takahashi; Cristiane de S Rocha; Benilton de Sá Carvalho; Cláudia V Maurer-Morelli; Silvana R P Orrico; Silvana P Barros; Raquel M Scarel-Caminaga
Journal:  Sci Rep       Date:  2020-05-18       Impact factor: 4.379

Review 5.  The Effects of Antioxidants from Natural Products on Obesity, Dyslipidemia, Diabetes and Their Molecular Signaling Mechanism.

Authors:  Chindiana Khutami; Sri Adi Sumiwi; Nur Kusaira Khairul Ikram; Muchtaridi Muchtaridi
Journal:  Int J Mol Sci       Date:  2022-02-12       Impact factor: 5.923

6.  Folic acid deficiency increases sensitivity to DNA damage by glucose and methylglyoxal.

Authors:  Leigh Donnellan; Bradley S Simpson; Varinderpal S Dhillon; Maurizio Costabile; Michael Fenech; Permal Deo
Journal:  Mutagenesis       Date:  2022-04-02       Impact factor: 2.954

7.  Increased Micronuclei Frequency in Oral and Lingual Epithelium of Treated Diabetes Mellitus Patients.

Authors:  Jesús Emilo Quintero Ojeda; Maribel Aguilar-Medina; Vicente Olimón-Andalón; Rosa Alicia García Jau; Alfredo Ayala Ham; José Geovanni Romero Quintana; Erika de Lourdes Silva-Benítez; Guzmán Sanchez-Schmitz; Rosalío Ramos-Payán
Journal:  Biomed Res Int       Date:  2018-01-09       Impact factor: 3.411

8.  Using association rule mining to jointly detect clinical features and differentially expressed genes related to chronic inflammatory diseases.

Authors:  Rosana Veroneze; Sâmia Cruz Tfaile Corbi; Bárbara Roque da Silva; Cristiane de S Rocha; Cláudia V Maurer-Morelli; Silvana Regina Perez Orrico; Joni A Cirelli; Fernando J Von Zuben; Raquel Mantuaneli Scarel-Caminaga
Journal:  PLoS One       Date:  2020-10-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.